Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic study shows benefits of IN.PACT Admiral drug-coated balloon

Medtronic study shows benefits of IN.PACT Admiral drug-coated balloon

24th December 2014

Medtronic has announced new data from a landmark clinical trial that demonstrates the benefits offered by its IN.PACT Admiral drug-coated balloon.

Published in the medical journal Circulation, the study showed that the device was able to significantly outperform standard balloon angioplasty in the treatment of symptomatic peripheral artery disease of the superficial femoral and proximal popliteal arteries.

Moreover, those treated with IN.PACT Admiral experienced the highest rate of primary patency and the lowest rate of clinically-driven target lesion revascularisation at 12 months ever reported from a study of interventional treatments for this form of the disease.

Medtronic received European CE Mark approval for the drug in 2009, but it remains limited to investigational use in the US.

The study authors said the device "stands to become an important treatment option for patients with superficial femoral and popliteal artery disease".

Last week, the firm completed global user evaluations of a next-generation system that uses a new insulin pump platform, marking a key step toward development of an artificial pancreas.ADNFCR-8000103-ID-801767584-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.